2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2157 BCL-2 inhibition by surzetoclax enhances activity of etentamig through tumor-intrinsic and T-cell-specific mechanisms in multiple myeloma

David Sharon, PhD, Michelle Belmont2, Valerie Robinson3, Durga Dandamudi4, Claudie Hecquet5, Adam Chervin6, PK Epling-Burnette, PhD, PharmD7, Jason G Harb, PhD8
1 AbbVie Inc., North Chicago, Illinois, United States
2 AbbVie Inc., North Chicago, Illinois, United States
3 AbbVie Inc., North Chicago, Illinois, United States
4 AbbVie Inc., North Chicago, Illinois, United States
5 AbbVie Inc., North Chicago, Illinois, United States
6 AbbVie Inc., North Chicago, Illinois, United States
7 AbbVie Inc., North Chicago, Illinois, United States
8 AbbVie Inc., North Chicago, Illinois, United States

BCL-2 inhibition is an effective therapeutic strategy in biomarker-selected, BCL-2-high and/or t(11;14) relapsed/refractory (R/R) multiple myeloma (MM), where disease survival depends on BCL-2 (Kumar et al., Blood 2017). Surzetoclax (surze) (Phillips et al., Blood 2024) is a next-generation BCL-2 inhibitor currently being investigated as monotherapy (NCT05308654) and in combination with other anti-myeloma agents (NCT06953960) in this biomarker-defined patient population. In addition to direct antitumor activity, BCL-2 inhibitors suppress Treg function and differentiation, which may enhance T-cell immunotherapies such as etentamig (etenta), a next-generation B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager (TCE). Studies have shown that higher baseline Treg levels are associated with reduced TCE responses and progressive disease, suggesting that Treg depletion may overcome resistance or prolong response duration. The objective of this study was to determine whether surze enhances the activity of etenta by reducing the induction and/or suppressive activity of Tregs in ex vivo models of MM.

 

To determine whether surze enhances the activity of etenta, redirected T-cell cytotoxicity assays were performed using healthy donor CD3+ T cells and tumor cell lines with different genetic and biomarker backgrounds: t(11;14) (KMS-12-BM, U266-B1) and non-t(11;14) (RPMI-8226, LP-1, OPM-2, and NCI-H929). A 12-point dose-response curve for etentamig was established in all cell lines, and results showed high sensitivity independent of genotype (average EC50 1.88 nM ± 3.0 SD). Combination experiments were conducted at the EC50 of etentamig for each cell line with 2–3 fixed concentrations of surze, and results were compared with a negative control. A lower EC50 was observed for the combination compared with single-agent etenta (1.25 nM ± 2.2 SD), representing an average 2.2-fold reduction (range, 1.3–3.5-fold), with RPMI-8226 showing the greatest improvement in cell lysis.

 

As T-cell-engaging (TCE) antibodies have been shown to promote conversion of conventional CD4 T cells to a FOXP3+ regulatory T-cell phenotype (Treg) (Casey et al., Cell Ther Immunother 2024), flow cytometric analysis was used to identify FOXP3+, CD25-high CD4 T cells (Tregs) in RPMI-8226/PBMC cultures. Compared with single-agent etenta experiments using PBMCs from healthy donors (n=6) or MM patients (n=10), Treg induction was significantly lower with the surze/etenta combination, suggesting that Tregs may be suppressed by surze-mediated BCL-2 inhibition. To determine whether surze-mediated Treg depletion enhances etenta antitumor activity, exogenously activated immunosuppressive Tregs from healthy donors were added to RPMI-8226/PBMC co-cultures. As expected, suppression of etenta-mediated MM cell growth occurred due to the addition of Tregs at a 1:1 ratio with effector cells (PBMCs). Addition of surze reversed Treg suppressive function and restored etentamig antitumor activity to levels seen in culture without Tregs.

 

Fully suppressive Treg development occurs over an extended culture period following TCE exposure; therefore, the impact of the surze/etenta combination was assessed in long-term (21-day) cultures. On day 21, CD8+ T-cell activation was greater with the combination (45% vs 18%). A 50% reduction in Tregs was also observed with the combination, suggesting that surze plays a positive role in etenta-activated CD8+ T-cell homeostasis. Because chronic activation is associated with T-cell exhaustion in the presence of continuous tumor exposure, TOX+PD-1+ CD8+ T cells were also examined. A higher percentage of exhausted T cells was observed on day 21 with single-agent etenta, and a 5-fold reduction was seen with the surze+etenta combination.

 

Taken together, these studies indicate that BCL-2 inhibition by surze may enhance the activity of TCEs through both tumor-intrinsic effects and T-cell modulation. The surze+etenta combination is currently being investigated in substudy 3 of the M25-275 platform study (NCT06953960).

David Sharon, PhD: AbbVie Inc. - Current equity holder in publicly-traded company; AbbVie Inc. - Stock (publicly traded); AbbVie Inc. - Current Employment